We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

“BridgIT” Identifies Candidate Genes and Catalyzing Proteins for Orphan and Novel Enzyme Reactions

News   Mar 28, 2019 | Original story from EPFL

 
“BridgIT” Identifies Candidate Genes and Catalyzing Proteins for Orphan and Novel Enzyme Reactions

The computational tool BridgIT assigns genes and proteins to orphan and novel hypothetical reactions by studying the reactive sight of an enzymatic reaction as well as the surrounding atoms. Credit: EPFL

 
 
 

RELATED ARTICLES

Gene Therapy for Duchenne Muscular Dystrophy Successful in Pigs

News

An interdisciplinary Munich research team led by scientists from TUM has for the first time succeeded in correcting the mutated dystrophin gene in living pigs. In order to cut the defective gene sequence from the DNA of the animals' muscle and heart cells, the researchers modified the Crispr-Cas9 gene scissors.

READ MORE

Human Body-on-Chip Systems Boost Drug Testing Capabilities

News

A team of researchers has designed a comprehensive multi-organ-on-a-chip platform that supports effective in vitro-to-in vivo translation of human drug pharmacology.

READ MORE

Novel Cellular Entry Factor for Viral Vectors Used in Gene Therapy

News

Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types--the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles--that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE